Can I read PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicine on EtoBox?

PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicine by Elisa Baldelli; K Alex Hodge; Guido Bellezza; Neil J Shah; Guido Gambara; Angelo Sidoni; Martina Mandarano; Chamodya Ruhunusiri; Bryant Dunetz; Maysa Abu-Khalaf; Julia Wulfkuhle; Rosa I Gallagher; Lance Liotta; Johann de Bono; Niven Mehra; Ruth Riisnaes; Antonella Ravaggi; Franco Odicino; Maria Isabella Sereni; Matthew Blackburn; Angela Zupa; Giuseppina Improta; Perry Demsko; Lucio Crino'; Vienna Ludovini; Giuseppe Giaccone; Emanuel F Petricoin; Mariaelena Pierobon is a Medicine article available to read on EtoBox.

What is PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicine about?

## Background Anti-programmed cell death protein 1 and programmed cell death ligand 1 (PD-L1) agents are broadly used in first-line and second-line treatment across different tumor types. While immunohistochemistry-based assays are routinely used to assess PD-L1 expression, their clinical utility remains controversial due to the partial predictive value and lack of standardized cut-offs across antibody clones. Using a high throughput immunoassay, the reverse phase protein microarray (RPPA), coupled with a fluorescence-based detection system, this study compared the performance of six anti-PD-L1 antibody clones on 666 tumor samples. ## Methods PD-L1 expression was measured using five antibody clones (22C3, 28–8, CAL10, E1L3N and SP142) and the therapeutic antibody atezolizumab on 222 lung, 71 ovarian, 52 prostate and 267 breast cancers, and 54 metastatic lesions. To capture clinically relevant variables, our cohort included frozen and formalin-fixed paraffin-embedded samples, surgical specimens and core needle biopsies. Pure tumor epithelia were isolated using laser capture microdissection from 602 samples. Correlation coefficients were calculated to assess concordance between antib

Who reads PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicine?

Author

Elisa Baldelli; K Alex Hodge; Guido Bellezza; Neil J Shah; Guido Gambara; Angelo Sidoni; Martina Mandarano; Chamodya Ruhunusiri; Bryant Dunetz; Maysa Abu-Khalaf; Julia Wulfkuhle; Rosa I Gallagher; Lance Liotta; Johann de Bono; Niven Mehra; Ruth Riisnaes; Antonella Ravaggi; Franco Odicino; Maria Isabella Sereni; Matthew Blackburn; Angela Zupa; Giuseppina Improta; Perry Demsko; Lucio Crino'; Vienna Ludovini; Giuseppe Giaccone; Emanuel F Petricoin; Mariaelena Pierobon

Publisher

BMJ

Published

2021

Language

EN

Field

Medicine (Health Sciences)